| CLBS Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the CLBS shares outstanding history going back to 8/5/2016:
Also see: CLBS Market Cap History CLBS YTD Return |
CLBS Shares Outstanding History — Caladrius Biosciences Share Count Over Time
As of 8/4/2022 Caladrius Biosciences has 60.58 million CLBS shares outstanding. Investors often track the CLBS shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows CLBS share count trends over time, with 26 historical shares outstanding datapoints presented, dating back to 8/5/2016.
| CLBS Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLBS Historical Shares Outstanding: +47.37% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CLBS Stock Price Chart |
| About Lisata Therapeutics Inc |
| Caladrius Biosciences is a clinical-stage biopharmaceutical company focused on the development of treatments and reversal of severe diseases. Co.'s product candidates include: XOWNA®, which is a Phase 2a study and an ongoing follow-on Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction; HONEDRA®, which is eligible for early conditional approval in Japan for the treatment of critical limb ischemia based on the results of a clinical trial; and CLBS201, which is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes. We show 26 historical shares outstanding datapoints in our coverage of CLBS's shares outstanding history. Understanding the changing numbers of CLBS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CLBS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CLBS by allowing them to research CLBS shares outstanding history as well as any other stock in our coverage universe. |
| CLBS Current Stock Quote |
Quotes delayed 20 minutes  Free CLBS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| CLBS Share Performance |
| Shares Outstanding Peers |
| Caladrius Biosciences (CLBS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
CLDX Shares Outstanding History CLNN Shares Outstanding History CLOV Shares Outstanding History CLPT Shares Outstanding History CLRB Shares Outstanding History CLSD Shares Outstanding History CLSN Shares Outstanding History CLVS Shares Outstanding History CLXT Shares Outstanding History CLYM Shares Outstanding History More Healthcare companies » |
CLBS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
